ALP Bio raises €161K for safer biologics
ALP Bio’s early funding points to a more specific use of AI in biotech: predicting immune-related risks in biologic medicines.
AI in biotech is becoming more specific. The story is no longer only about discovering new drugs faster; it is also about reducing risk earlier in development.
What happened
Swiss biotech startup ALP Bio secured €161K / CHF 150K from Venture Kick to develop an AI-powered platform for improving the safety of biologic medicines.
The company is working on a system that combines human immune tissue models with protein modelling to help identify immune-related risks earlier in biologic drug development.
Why it matters
The funding amount is small, but the technical signal is useful. Biologic medicines can be powerful, but they also carry risks around how the immune system responds. Identifying those risks earlier could reduce development failures and make preclinical testing more informative.
This is a narrower and more credible AI-biotech angle than broad claims about “AI discovering everything.” It focuses on a specific bottleneck: safety prediction for complex medicines.
The bigger picture
The strongest AI life-sciences startups may not be the ones making the biggest promises. They may be the ones applying AI to well-defined scientific workflows where better prediction can save time, money and clinical risk.
ALP Bio is still very early, but it fits the broader trend of AI moving deeper into drug development infrastructure, from target discovery to toxicology, immunogenicity and trial design.